Clinical Trial Details
EORTC-62024
Back to Clinical Trials Database
Intermediate and high risk localized,completely resected, gastrointestinal stromal tumors (GIST) expressing KIT receptor : a controlled randomized trial on adjuvant Imatinib mesylate (Glivec) versus no further therapy after complete surgery.
Trial Status | All trial activities ended |
---|---|
Dates |
Date of activation: 08-Dec-2004 Date Step1 close: 20-Oct-2008 |
Data management at EORTC | Yes |
Design |
Phase 3 Randomized open label |
Targeted Sample size | EORTC Groups: 350 - All Groups: 900 |
Treatment | |
Study Staff | |
Type of cancer | |
Participating groups | |
Protocol summary | http://clinicaltrials.gov/study/NCT00103168 |
NCT number | NCT00103168 |
EudraCT | 2004-001810-16 |